XTL Biopharmaceuticals Announces Appointment of Samuel H. Rudman to Board of Directors

    VALLEY COTTAGE, N.Y., Aug. 14 /EMWNews/ -- XTL

Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) today announced that

Samuel H. Rudman, Esq., has been appointed to XTL's Board of Directors,

effective as of August 13, 2008.



    Mr. Rudman, 40, is a named partner at a U.S. law firm specializing in

complex litigation, emphasizing securities, consumer, insurance,

healthcare, human rights, employment discrimination and antitrust class

actions. Mr. Rudman's practice is focused primarily on the area of

securities and shareholder litigation, and complex issues of disclosure and

corporate governance.



    Mr. Rudman graduated with a BA in political science from Binghamton

University and with a JD from Brooklyn Law School.



    Ron Bentsur, Chief Executive Officer of XTL, commented "We are excited

to have Sam join our Board of Directors. Sam is well-versed in matters

related to corporate governance. We believe that his skills provide a

valuable addition to XTL's Board, as we prepare for the next stage of the

company's growth following what we hope will be a successful completion of

our Phase 2b study of Bicifadine in Q4 2008."



    ABOUT XTL BIOPHARMACEUTICALS LTD.



    XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of

therapeutics for the treatment of diabetic neuropathic pain and HCV. XTL is

developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor,

for the treatment of diabetic neuropathic pain, which is currently in a

Phase 2b study. XTL has out-licensed its novel pre-clinical HCV small

molecule inhibitor program. XTL also has an active in-licensing and

acquisition program designed to identify and acquire additional drug

candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock

Exchanges (NASDAQ: XTLB; TASE: XTL).



    Cautionary Statement



    Some of the statements included in this press release, particularly

those anticipating future clinical and business prospects for our clinical

compound for neuropathic pain, Bicifadine, growth and operating strategies

and similar matters, may be forward-looking statements that involve a

number of risks and uncertainties. For those statements, we claim the

protection of the safe harbor for forward-looking statements contained in

the Private Securities Litigation Reform Act of 1995. Among the factors

that could cause our actual results to differ materially is our ability to

complete in a timely and cost effective manner clinical trials on

Bicifadine, which could directly impact our ability to continue to fund our

operations; our ability to meet anticipated development timelines for all

of our drug candidates due to recruitment, clinical trial results,

manufacturing capabilities or other factors; our ability to obtain

regulatory approvals for commercial sale of our products; the success of

our drug development and marketing arrangements with third parties; and

other risk factors identified from time to time in our reports filed with

the Securities and Exchange Commission, including our annual report on Form

20-F filed with the Securities and Exchange Commission on March 27, 2008.

Any forward-looking statements set forth in this press release speak only

as of the date of this press release. We do not intend to update any of

these forward-looking statements to reflect events or circumstances that

occur after the date hereof. This press release and prior releases are

available at http://www.xtlbio.com. The information in our website is not

incorporated by reference into this press release and is included as an

inactive textual reference only.